Clinical Trials Logo

Clinical Trial Summary

Severe hypoglycemia is the most feared complication of medications used to lower blood glucose levels in patients with diabetes. Severe hypoglycemia, defined as plasma glucose low enough to require assistance, has been linked to poor health-related quality of life, emotional and interpersonal challenges, car accidents, serious falls, cardiovascular events, dementia, and death. Older adults with type 2 diabetes are particularly vulnerable to the complications of severe hypoglycemia. Each year, approximately 11% of patients with type 2 diabetes self-report severe hypoglycemia episodes. An estimated 14% of emergency hospitalizations of older Americans for adverse drug events implicate insulin and 11% implicate oral hypoglycemic agents. One in four diabetes-related hospital admissions is for hypoglycemia. This study will compare two ways to reduce severe hypoglycemia in people with type 2 diabetes. The two methods to be compared are: 1. Proactive care management. This will be a nurse outreach call which is similar to the usual care that people with type 2 diabetes get to reduce their risk of severe hypoglycemia, but given in advance rather than in response to a recent severe hypoglycemia event. 2. The same proactive care management (nurse outreach call) plus enrollment in my hypo compass, a health education program aimed at improving awareness of hypoglycemia and preventing severe hypoglycemia. This program has been shown to reduce severe hypoglycemia in people with type 1 diabetes but has not been tested in persons with type 2. Our hypothesis is that proactive care management plus my hypo compass will be more effective than proactive care management alone at preventing self-reported severe hypoglycemia in adults with type 2 diabetes at high risk for severe hypoglycemia. The primary outcome will be measured using surveys at the beginning of the study and 14-months later.

Clinical Trial Description

This study is a two-arm (128 per arm), cluster-randomized, comparative effectiveness study of two evidence-based approaches to preventing severe hypoglycemia. We will use a validated Electronic Health Record (EHR)-based tool to identify patients with type 2 diabetes at intermediate to high risk for severe hypoglycemia. Within this population, we will recruit participants who either have impaired awareness of hypoglycemia or self-report a severe hypoglycemia event in the prior 12 months and are 50 years or older. Participants must be members of Kaiser Permanente Washington and identified by the study. Following randomization, we will compare patients who receive proactive care management from nurses to patients receiving proactive care management plus my hypo compass, a structured educational intervention that reduces the frequency of severe hypoglycemia in individuals with type 1 diabetes. In both groups, we will use proactive care management to assess and provide evidence-based care for impaired awareness of hypoglycemia and other potential contributors to severe hypoglycemia risk. Our primary outcome is participant-reported severe hypoglycemia, to capture all events, including those not involving clinical care. We will also examine biochemical measures of hypoglycemia measured using continuous glucose monitoring (CGM), participant-reported hypoglycemia awareness, fear of hypoglycemia, and emergency department visits and hospitalizations for severe hypoglycemia. We will conduct a process evaluation to assess the fidelity of implementation and clarify the causal pathway. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04863872
Study type Interventional
Source Kaiser Permanente
Contact Kelly J Ehrlich, MS
Phone 206-287-2381
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date July 19, 2021
Completion date April 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Recruiting NCT04786262 - A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes Phase 1/Phase 2
Completed NCT03439072 - G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Completed NCT02969343 - Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered N/A